Bioequivalence of two formulations of montelukast sodium 4 mg oral granules in healthy adults

Clinical and Translational Allergy

Volumn 4, Issue 1, 2014, Pages

  Fey, Constanze ^a   Thyroff Friesinger, Ursula ^a   Jones, Spencer ^b  

^a Sandoz Biopharmaceuticals   (Germany)

^b Sandoz Pharma Ltd   (Switzerland)

Author keywords

4 mg oral granules; Asthma; Bioequivalence; Montelukast; Rhinitis; Sandoz; Singulair mini

Indexed keywords

MONTELUKAST;

ADULT; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DYSPEPSIA; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84978025208     PISSN: None     EISSN: 20457022     Source Type: Journal    
DOI: 10.1186/2045-7022-4-29     Document Type: Article

References (15)

1. Sandoz: SPC: Montelukast Sodium 4 mg Oral Granules. 2013. http://www. medicines.org.uk/emc/medicine/27591.
2. Merck: Prescribing Information Singulair®. 2013. http://www.merck.com/product/usa/pi-circulars/s/singulair/singulair-pi.pdf.
3. Migoya E, Kearns GL, Hartford A, Zhao J, van Adelsberg J, Tozzi CA, Knorr B, Deutsch P: Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J Clin Pharmacol 2004, 44: 487-494.
4. US Food and Drug Administration: FDA Approves First Generic Versions of Singulair to Treat Asthma, allergies. 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm314436.htm.
5. European Medicines Agency Committee for Medicinal Products for Human Use: Guideline On The Role Of Pharmacokinetics In The Development Of Medicinal Products In The Paediatric Population. http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003066.pdf.
6. European Medicines Agency Committee for Medicinal Products for Human Use: Guideline On The Investigation Of Bioequivalence. European Medicines Agency; 2010. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/01/WC500070039.pdf.
7. Dunne S, Shannon B, Dunne C, Cullen W: A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol 2013, 14: 1.
8. Scaparrotta A, Di Pillo S, Attanasi M, Rapino D, Cingolani A, Consilvio NP, Verini M, Chiarelli F: Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma. Multidiscip Respir Med 2012, 7(1): 13.
9. Blake KV: Montelukast: data from clinical trials in the management of asthma. Ann Pharmacother 1999, 33(12): 1299-1314.
10. Bozek A, Warkocka-Szoltysek B, Filipowska-Gronska A, Jarzab J: Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. J Asthma 2012, 49(5): 530-534.
11. Ducharme FM, Noya FJ, Allen-Ramey FC, Maiese EM, Gingras J, Blais L: Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors. Curr Med Res Opin 2012, 28(1): 111-119.
12. Keith PK, Koch C, Djandji M, Bouchard J, Psaradellis E, Sampalis JS, Schellenberg RR, McIvor RA: Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009, 16(Suppl A): 17A-31A.
13. Cingi C, Gunhan K, Gage-White L, Unlu H: Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope 2010, 120(9): 1718-1723.
14. Modgill V, Badyal DK, Verghese A: Efficacy and safety of montelukast add-on therapy in allergic rhinitis. Methods Find Exp Clin Pharmacol 2010, 32(9): 669-674.
15. Yamamoto H, Yamada T, Sakashita M, Kubo S, Susuki D, Tokunaga T, Ogi K, Terasawa Y, Yamashita S, Kayano Y, Masada M, Kimura Y, Fujieda S: Efficacy of prophylactic treatment with montelukast and montelukast plus add-on loratadine for seasonal allergic rhinitis. Allergy Asthma Proc 2012, 33(2): e17-e22.